Title: Neuronal alpha-Synuclein Disease Integrated Staging System performance in PPMI, PASADENA, and SPARK baseline cohorts.

Authors: Tien Dam, MD[1], Gennaro Pagano, MD[2], Michael C Brumm, MS[3], Caroline Gochanour, MS[3], Kathleen L Poston, MD[4], Daniel Weintraub, MD[5], Lana M. Chahine, MD[6], Christopher Coffey, PhD[3], Caroline M. Tanner, PhD[7], Catherine M. Kopil, PhD[8], Yuge Xiao, BS[8], Sohini Chowdhury, MA[8], Luis Concha-Marambio, PhD[9], Peter DiBiaso, MHSA[10,11], Tatiana Foroud, PhD[12], Mark Frasier, PhD[8], Danna Jennings, MD[13], Karl Kieburtz, MD[14], Kalpana Merchant, PhD[15], Brit Mollenhauer, MD[16], Thomas J Montine, MD[17], Kelly Nudelman, PhD[12], John Seibyl, MD[18], Todd Sherer, PhD[8], Andrew Singleton, PhD[19], Diane Stephenson, PhD[20], Matthew Stern, MD[21], Claudio Soto, PhD[9,22], Eduardo Tolosa, MD[23], Andrew Siderowf, MD[21], Billy Dunn, MD[24], Tanya Simuni, MD[15], Kenneth Marek, MD[18] and the Parkinson's Progression Markers Initiative*.

1. Biogen, Boston, MA, USA.
2. F. Hoffmann-La Roche Ltd., Basel, Switzerland.
3. Department of Biostatistics, College of Public Health, University of Iowa, Iowa City, IA, USA.
4. Department of Neurology, Stanford University School of Medicine, Palo Alto, CA, USA.
5. University of Pennsylvania and the Parkinson's Disease and Mental Illness Research, Education and Clinical Centers (PADRECC and MIRECC), Philadelphia Veterans Affairs Medical Center
6. Department of Neurology, University of Pittsburgh, Pittsburgh, PA, USA.
7. Movement Disorders and Neuromodulation Center, Department of Neurology, Weill Institute for Neuroscience, University of California, San Francisco, CA, USA.
8. The Michael J. Fox Foundation for Parkinson's Research, New York, NY, USA.
9. Amprion Inc., San Diego, CA, USA.
10. Patient Council, The Michael J. Fox Foundation for Parkinson's Research, New York, NY, USA
11. Clinical Solutions and Strategic Partnerships, WCG Clinical, Princeton, NJ, USA.
12. Department of Medical and Molecular Genetics, Indiana University, Indianapolis, IN, USA.
13. Denali Therapeutics Inc., South San Francisco, CA, USA.
14. Department of Neurology, University of Rochester Medical Center, Rochester, NY, USA.
15. Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
16. Department of Neurology, University Medical Center Göttingen and Paracelsus-Elena-Klinik, Kassel, Germany.
17. Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA.
18. Institute for Neurodegenerative Disorders, New Haven, CT, USA.
19. National Institute on Aging, National Institutes of Health, Bethesda, MD, USA.
20. Critical Path for Parkinson's, Critical Path Institute, Tucson, AZ, USA.
21. Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
22. Mitchell Center for Alzheimer's Disease and Related Brain Disorders, Department of Neurology, University of Texas McGovern Medical School at Houston, Houston, TX, USA
23. Parkinson's Disease and Movement Disorders Unit, Neurology Service, Hospital Clínic de Barcelona, Barcelona, Spain; Centro de Investigación Biomédica en Red Sobre Enfermedades Neurodegenerativas (CIBERNED), Hospital Clínic, IDIBAPS, Universitat de Barcelona, Barcelona, Spain.
24. Senior Advisor, The Michael J. Fox Foundation for Parkinson's Research, New York, NY, USA.

Corresponding Author

Tanya Simuni, MD
Department of Neurology
Northwestern University Feinberg School of Medicine
710 North Lake Shore Drive, 1126
Chicago, IL 60611
Phone 312-503-2970
Fax 312-908-5073
tsimuni@nm.org

Abstract word count: 300
Manuscript word count: 3539 (includes references author & year)
Title Character Count (with spaces): 143

Tables: 3
Figures: 2
Supplementary: 4 Tables and 1 Figures

Running title: Application of Neuronal Alpha-Synuclein Disease
Key words: Biological definition, Neuronal Alpha-Synuclein Disease**,** Parkinson's disease, Dementia with Lewy Bodies

ABSTRACT

The Neuronal alpha-Synuclein Disease (NSD) biological definition and Integrated Staging System (NSD-ISS) provide a research framework to identify individuals with underlying Lewy body pathology, including Parkinson's disease (PD), Parkinson's disease dementia, and dementia with Lewy bodies (DLB), and stage them based on underlying biology and increasing degree of functional impairment. The objectives of this paper were to 1) develop both biologic and clinical data-informed definitions for the NSD-ISS; 2) apply these definitions across the disease continuum; and 3) evaluate time to onset of key clinical outcomes based on baseline NSD stage.

Methods
We utilized data from the PPMI, an observational study and PASADENA and SPARK, two independent interventional studies. Individuals currently defined by clinical features as PD, Prodromal, or Healthy Controls were classified based on biological, clinical, and functional anchors and assigned to one of seven NSD-ISS stages at baseline. Biomarker anchors included synuclein (S) assessed by cerebrospinal fluid (CSF) alpha-synuclein seed amplification assay (n-asyn SAA), dopamine (D) assessed by dopamine transporter imaging (DaTscan), and genetic status (G). Clinical and functional anchors were derived from MDS-UPDRS Parts I-III and the Montreal Cognitive Assessment. The onset of key clinical outcomes for each stage was assessed over 12 years of follow-up.

Results
Across the three studies 1,741 participants had SAA data and of these 1,030 (59%) were S+ consistent with NSD. Among sporadic PD, 683/736 (93%) were NSD and the distribution for Stages 2B, 3, and 4 was 25%, 63%, and 9%, respectively. Among these individuals, median (95% CI) time to developing a clinical outcome was 8.3 (6.2, 10.1), 5.9 (4.1, 6.0), and 2.4 (1.0, 4.0) years for those staged at baseline as 2B, 3, and 4, respectively.

Conclusion
We propose data driven biologic and clinical anchors for NSD-ISS. Our data highlight baseline heterogeneity of the individuals currently defined as early PD that impacts progression to clinically meaningful milestones. Validation of the anchors in longitudinal cohorts is necessary.

INTRODUCTION

We recently proposed a new research biological definition for Neuronal alpha-Synuclein Disease (NSD) and an integrated staging system (NSD-ISS)[1] enabled by the development and validation of assays that can accurately detect misfolded neuronal alpha-synuclein (n-asyn) *in vivo*[2]. This biological definition is grounded on three key tenets: 1) a disease is defined biologically based on validated *in-vivo* biomarkers; 2) the disease can be diagnosed in absence of clinical manifestations ; and 3) the same biology may result in different phenotypic presentations; thus, symptoms are a result of the disease process but do not define it. As such, diagnosis is based on disease-specific biomarkers, and symptoms are not necessary for diagnosis. This biological definition is a departure from traditional clinical diagnostic criteria of Parkinson's disease (PD) and dementia with Lewy bodies (DLB)[3][4], which are linked by the same aggregates of n-asyn found predominantly in neuronal cell bodies and neurites, but diverge based on the predominance of motor versus cognitive symptoms at initial clinical manifestation.

NSD is a unifying term that encompasses PD, DLB, and any other n-asyn driven clinical syndrome. We have further proposed the NSD-ISS which integrates the biological substrates of the disease, n-asyn (S) and dopaminergic dysfunction (D), with cognitive, other non-motor, or motor manifestations and functional impairment to define stages along the NSD continuum. The intent of the NSD-ISS is to provide an integrated biological and clinical framework to expand understanding of disease and advance biologically targeted therapeutic development.

The NSD-ISS proposed seven distinct stages: Stage 0 (presence of fully penetrant pathogenic variants in *SNCA* gene); Stage 1 (presence of n-asyn alone (Stage 1A) or in combination with dopaminergic dysfunction (Stage 1B), asymptomatic); Stage 2 (presence of n-asyn alone (Stage 2A) or in combination with dopaminergic dysfunction (Stage 2B), and subtle clinical signs/symptoms without functional impairment); and Stages 3-6 (presence of both n-asyn and dopaminergic dysfunction, and clinical signs/symptoms with progressively increasing severity of functional impairment).

Simuni et al. outlined the staging framework in a Position paper[1] . The objectives of this study were to 1) develop operational biologic and clinical definitions for the NSD-ISS stages 2-6 utilizing currently available clinical scales; 2) apply these definitions across the disease continuum utilizing available data in three well characterized studies; and 3) evaluate time to onset of key clinical outcomes based on baseline NSD stage.

METHODS

Participants and Study Designs

Participant-level data from three independent studies were available: Parkinson's Progression Markers Initiative (PPMI), PASADENA and SPARK. Respective study aims and methodology have been published elsewhere[5-7]. All studies and recruitment materials were approved by institutional review boards or ethics committee at each site. Written informed consent was obtained from all participants before undergoing any study evaluations. Clinical trials were performed in accordance with the principles outlined in the Declaration of Helsinki and with Good Clinical Practice guidelines.

Briefly, the PPMI (NCT01141023) study is a multinational, prospective longitudinal observational study launched in 2010[5] with three cohorts: clinically diagnosed early PD, prodromal, or non-manifesting carriers of genetic variants associated with PD, and healthy controls (HC). Individuals with PD were enrolled if they were within 2 years of diagnosis, Hoehn and Yahr (H&Y) stage 1–2, not on PD medications at the time of enrollment, and had an abnormal dopamine transporter (DAT)imaging scan with single-photon-emission computed tomography (SPECT). Inclusion criteria for the genetic PD cohort were the same, except for PD medications and diagnosis within 7 years were allowed. Prodromal participants had prodromal features associated with risk of PD, including severe hyposmia as measured by the University of Pennsylvania Smell Identification Test (UPSIT) based on internal population norms[8] or REM sleep behavior disorder (RBD) confirmed by polysomnogram. Healthy controls were similar age- and sex individuals without known neurological signs or symptoms and normal DAT imaging. All PPMI participants undergo extensive clinical phenotypic and biological characterization annually that includes collection of cerebrospinal fluid (CSF) samples and DAT imaging. All participants undergo whole genome sequencing after recruitment, and participants with relevant genetic variants are analyzed accordingly.

PASADENA (NCT03100149) was a phase 2, multinational, double-blind, randomized controlled trial examining the efficacy and safety of prasinezumab in 316 individuals with early PD who received intravenous prasinezumab (1500 mg or 4500 mg) or placebo every 4 weeks for 52 weeks[6] .

SPARK (NCT03318523) was a phase 2, multinational, double-blind, randomized controlled trial that examined the efficacy and safety of cinpanemab in 357 individuals with early-stage PD were assigned to receive one of three doses (250 mg, 1250 mg, or 3500 mg) intravenous cinpanemab or placebo every 4 weeks for 52 weeks, after which placebo recipients switched to cinpanemab[7] .

Participants from all three studies underwent a series of clinical assessments described previously[5-7]. Relevant assessments included the Montreal Cognitive assessment (MoCA)[9] and the Movement Disorders Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) parts I (non-motor aspects or experiences of daily living), II (motor aspects or experiences of daily living), and III (motor examination; recorded in the off-state for treated participants)[10]. Lumbar punctures for CSF was required at baseline for PPMI and was collected in a subset of participants in both PASADENA and SPARK,.

Biologic and Clinical Anchors

The NSD-ISS Framework categorized individuals based on biologic (S, D, and G), clinical, and functional impairment anchors (Supplement Table 1)[1]. See Panel 1 for the glossary of terms.

S anchor: The presence of n-asyn was evaluated using a CSF α-synuclein (n-asyn) seed amplification assay (n-asyn SAA)[2,11-13]. Samples from the three studies followed the same sample processing procedures and were analyzed at a central laboratory using standardized assay conditions (Amprion). Each individual sample was analyzed in triplicate and determined to be either αSyn-SAA positive (S+) or negative (S-) according to a previously reported algorithm [14]. Some PPMI participants only had CSF n-asyn SAA evaluated at a follow-up visit; in such cases, participants were considered S+ if they tested positive within 12 months (PD cohort) or 6 months (other cohorts) of baseline, and were considered S- if they tested negative at any follow-up visit.

D anchor: The presence of dopamine dysfunction was evaluated in all 3 studies with DAT imaging using ^{123}I-ioflupane. Images were processed at a central laboratory with a standardized reconstruction algorithm and image analysis workflow (PMOD for PPMI and PASADENA, Hermes Medical Solutions for SPARK) and were analyzed visually by experienced nuclear medicine experts unaware of the trial-group assignments. Visual interpretation of the scan was used as a criterion for enrollment into PPMI PD cohorts, PASADENA, and SPARK. Quantitative assessment of specific binding ratio (SBR) in striatal regions was calculated using previously developed methods[15]. Lowest SBR adjusted for age and sex was used to determine DAT deficit for NSD-ISS staging. Individual with a putamen SBR ≤75% were designated as D+. Based on this quantitative criterion, an individual with dopamine dysfunction by visual inspection could be D-. Three PPMI PD participants underwent VMAT-2 imaging with 18F AV133 (not DAT imaging) and were assumed to be D+ based on visual inspection only.

G anchor: The criterion for Stage 0, defined strictly by G+ status was restricted to only fully penetrant pathogenic *SNCA* variants.

Process for Defining Anchors for Clinical and Functional Impairment

There are no universally accepted scales for assessment of overall clinical and functional impairment in PD and DLB. The NSD working group reviewed validated clinical outcome assessments (COAs); the selection criteria for these anchors were: (1) participant-reported severity of impairment across three clinical domains (cognitive, other non-motor, and motor domains) and (2) widely utilized in observational and interventional studies. Hence, the MDS-UPDRS and MoCA were selected, recognizing that a wide armamentarium of other COAs could have been utilized.

The NSD-ISS incorporates the presence of clinical signs or symptoms across three clinical domains, motor, cognitive, and non-motor symptoms. While the conceptual paper outlines a wide spectrum of motor and non-motor manifestations, including anxiety, depression, autonomic dysfunction, we recognize lack of specificity of such. Therefore, we have limited the non-motor symptoms for Stage 2 to the presence of hyposmia or RBD. Hyposmia was defined as UPSIT %ile ≤15 adjusted for age and sex[8]; RBD was defined by polysomnography-confirmed diagnostic criteria or clinical diagnosis (85% vs 15%). The MDS-UPDRS-III was used to evaluate motor signs/symptoms. In addition, we have not included non-motor symptoms as an anchor for Stage 3. Subthreshold parkinsonism, an anchor for Stage 2, was defined as MDS-UPDRS-III score ≥5, excluding the postural and action tremor items. This MDS-UPDRS -III cut-off was the mean plus two standard deviation among all PPMI healthy controls. Cognitive impairment for stage 2 was defined by MoCA total score <24 and MDS-UPDRS 1.1=1.

For the assessment of functional impairment, MDS-UPDRS-I total score and MDS-UPDRS-II total score were used to assess the severity of non-motor and motor functional impairment, respectively. Item 1.1 from MDS-UPDRS-I was used to assess cognitive functional impairment. The stage-based cut offs for MDS-UPDRS-I and II were selected iteratively by the NSD working group favoring a pragmatic approach. To obtain stage-specific cut-offs, we determined the upper limit for a stage by multiplying the number of items in each part (13 items) by the item severity score (i.e., slight=1, mild=2, moderate=3, severe =4). For example, a range of 14-26 was determined for Stage 4 to reflect clinical symptoms with mild functional impairment (calculation: 13 items multiplied by 2).

Integrated Staging System
Based on the anchors, individuals were then categorized into one of seven stages. Table 1 lists the biologic anchors and the stage-specific cut-offs for clinical and functional impairment anchors. Importantly, only S+ individuals qualify for staging (aside from SNCA carriers who are stage 0 independent of S status). Once individuals develop disease relevant clinical signs or symptoms across any of the 3 clinical domains, they advance to Stage 2. Individuals can be S+D- (Stage 2A) or S+D+ (Stage 2B) with subtle clinical signs/symptoms defined as having one or more of the following: MDS-UPRDS item 1.1 score of 1, RBD, hyposmia, subthreshold parkinsonism, or taking PD medications. For stage 3, individuals must be S+D+ with clinical signs/symptoms as Stage 2, but these clinical signs/symptoms cause slight functional impairment. For this analysis we have selected cognitive and motor domain: cognitive (defined as item 1.1 score AND MoCA ≤ 24) and motor (defined as MDS-UPDRS-II score between 3-13). Transition from Stage 2 to 3 does not incorporate total MDS-UPDRS Part I score due to lack of specificity of the non-motor domain in this early stage.

Progressively increasing impairment in any of the three domains, as measured by item 1.1, MDS-UPDRS-I total score or MDS-UPDRS-II total score, delineates Stages 4 through 6: mild (Stage 4), moderate (Stage 5), and severe (Stage 6) (Table 1).

Progression Milestones

To assess the impact of baseline staging on disease progression, we utilized a progression milestones approach described recently[16]. In brief, twenty-five key clinical outcomes, hereto forth termed progression milestones, spanning six clinical domains, including "walking and balance"; "motor complications"; "cognition"; "autonomic dysfunction"; "functional dependence"; and "activities of daily living", were examined. Milestones were chosen by a working group of clinical experts, based on knowledge of the existing literature and clinical experience, and intended to reflect an unambiguously clinically meaningful and functionally relevant degree of dysfunction (e.g., postural instability, motor fluctuations, cognitive impairment, urinary incontinence, loss of functional independence, choking). A composite binary endpoint, defined as time to first occurrence of any one of the milestones, was used to assess progression.

Statistical Analysis

Descriptive statistics at baseline, including mean and standard deviation (SD) for continuous measures and frequency (percentage) for categorical measures, were calculated by cohort and subgroup. Results were reported separately for NSD participants who could be staged, NSD participants who could not be staged, participants without NSD, and participants not evaluable for NSD. Among NSD participants who could be staged, baseline stage was tabulated by cohort and subgroup. To assess the relationship between baseline stage and clinical progression among PPMI sporadic PD participants in stages 2B through 4, nonparametric survival function plots using the EMICM algorithm with imputed standard errors for interval-censored data were generated for time from study enrollment to reaching any progression milestone, stratified by stage. Pointwise confidence limits of the survival function were obtained using a log-log transformation. Participants who did not reach a milestone or were lost to follow-up were right-censored. Participants were excluded from the analysis if they met milestone criteria at baseline and/or never completed any follow-up visits. Time to censoring and duration of follow-up were calculated as the number of years from the date of enrollment to last follow-up date. Figures were created using RStudio (Posit Software, PBC, Boston, MA; posit.co; RRID:SCR 000432). All other analyses were performed using SAS v9.4 (SAS Institute Inc., Cary, NC; sas.com; RRID:SCR 008567).

ROLE OF THE FUNDING SOURCE:

Research officers (SC, MF, CK, TS, YX) at MJFF, PPMI Sponsor, were involved in the design of the study and writing of the manuscript.

RESULTS

Participant Flow, Numbers Analyzed

Individual-level participant data available for each study are summarized in Figure 1. Participants without CSF samples for SAA testing and without an *SNCA* variant were considered not evaluable and excluded from analyses. Across the three studies, 1,741 participants with available CSF samples for αSyn-SAA testing and/or who carried an *SNCA* variant were included in analyses. Of these, 1,030 (59%) [859 PPMI, 61 PASADENA, 110 SPARK] were S+ and considered NSD, while 711 [694 PPMI, 6 PASADENA, and 11 SPARK] were S- and considered Not NSD.

Of the PPMI participants with a clinical diagnosis of PD, 88% were S+ including 100% of *SNCA* PD, 93% of sporadic PD and *GBA* PD, 64% of *LRRK2* PD, and 33% of *PRKN* PD. Most of the S- were among healthy controls and non-manifesting genetic cohorts, including 182 *LRRK2* non-manifesting carriers and 170 *GBA* non-manifesting carriers. In PASADENA and SPARK, 91% of early PD participants with CSF samples were S+.

Baseline Demographics

Table 2 shows baseline demographic characteristics of individuals with stageable NSD by study and recruitment cohort. Results were comparable between PPMI sporadic PD, PASADENA, and SPARK cohorts, considering difference in inclusion criteria. Consistent with the inclusion criteria, the genetic cohort in PPMI had longer disease duration at study entry.

Baseline characteristics are also presented for Not NSD (Supplement Table 3), Not evaluable (Supplement Table 3a) and NSD but not stageable (Supplement Table 3b) individuals.

Staging at Baseline

Out of 1,030 individuals with NSD, 56 PPMI participants were missing complete data (e.g., DAT, clinical measures) and not staged. Otherwise, the prevalence of each of the NSD-ISS stages within the PPMI, PASADENA, and SPARK studies are provided in Table 3. In PPMI, most individuals with clinically diagnosed early PD met criteria for stage 3 (65% sporadic PD, 61% *LRRK2* PD, and 59% *GBA* PD); similarly, 66% PASADENA and 55% SPARK participants were stage 3. Stage 2B was the second most prevalent stage with 25% PPMI sporadic PD, 26% PASADENA, and 25% SPARK. Additionally, 13% met stage 2A criteria in the SPARK trial (Supplement Figure 1). Across the PPMI RBD and hyposmic cohorts combined, most were stage 2A or 2B, 9% were stage 3, and 8% were stage 4 or 5. The number of non-manifesting carriers who had NSD across the genetic variants was very small (Figure 1) and the majority were in stage 1 and 2A (Table 3). Comparison of NSD-ISS by H&Y stage are presented in Supplement Table 4.

Progression Milestones

Among 504 PPMI sporadic PD participants in stages 2B-4, 37 (7%) who met milestone criteria at baseline (5 stage 2B [4%], 20 stage 3 [6%], 12 stage 4 [24%]) and 35 (7%) without follow-up data (9 stage 2B [7%], 24 stage 3 [7%], 2 stage 4 [4%]) were excluded from the analysis. Otherwise, during a mean clinical follow-up of 6.6 years, 248/432 participants (57%) experienced a new milestone (53/112 stage 2B [47%], 168/284 stage 3 [59%], 27/36 stage 4 [75%]). Individuals in stage 4 progressed fastest, with a median (95% CI) time to developing a new milestone of 2.4 (1.0, 4.0) years compared to 5.9 (4.1, 6.0) years and 8.3 (6.2, 10.1) years among individuals in stages 3 and 2B, respectively. (Figure 2).

DISCUSSION

We defined biologic and clinical anchors for NSD and for the first time applied stage-specific anchors of functional impairment to well-characterized observational (PPMI) and clinical trials (PASADENA and SPARK) that comprised of a broad spectrum of individuals identified as early PD, prodromal PD, non-manifesting carriers of genetic variants associated with PD, and healthy controls. Our data strongly supports the NSD-ISS conceptual framework and highlights several observations with direct relevance to therapeutic development.

Currently the field has been using clinically defined diagnostic criteria of PD or DLB. We deployed a pragmatic approach using existing scales to develop measures of worsening functional impairment within the NSD-ISS to establish a more homogenous and standardized staging system. Our analyses suggests that NSD is widely applicable and present in most individuals with the clinical phenotype of PD. Across the clinical PD spectrum, approximately 90% of individuals met criteria for NSD.

Application of the NSD-ISS highlights both the face validity of the NSD-ISS and the clinical heterogeneity of individuals currently identified as newly diagnosed PD. Our analyses suggest that approximately 63% of early PD individuals met criteria for Stage 3 (slight functional impairment) at baseline, consistent with expectations given the selected anchors for the stage. These individuals are the target for many clinical studies enrolling recently diagnosed untreated PD. However, on average 25% of individuals enrolled as early PD were stage 2B (with no functional impairment) and 9% were Stage 4 (with mild function impairment). Staging with NSD-ISS is also more dynamic and better differentiates severity than H&Y; individuals with H&Y stage 2 are distributed across Stage 2B to 4. In the PD genetic cohorts, the higher proportion of Stage 4 (25-44%) can be explained by the enrollment criteria which included individuals within 7 years of diagnosis and permitted PD medication use, again supporting face validity of the staging criteria. Finally, the NSD-ISS provides a standardized staging platform based on biomarkers and functional impairment that enables easy comparison and a common lexicon of clinical trials for both researchers and regulators.

NSD can identify individuals with unifying biology and highlights that the same disease is present across the clinical continuum, starting from no clinical manifestations to severe disease. Notably, 76% and 72% of individuals with RBD and hyposmia were S+. As such, these S+ individuals may now be eligible for future αSyn targeted therapies. These numbers may be higher compared to other studies as the PPMI prodromal cohort was enriched with individuals with positive DAT imaging. Not surprisingly, the prevalence of NSD was lower in at risk, asymptomatic individuals with genetic variants (8% of *LRRK2* NMC, 6% of *GBA* NMC) who may not develop or have delayed development of NSD.

Importantly, our findings highlight the artificial nature of the current separation between prodromal disease versus early PD. Approximately 25% of the sporadic PD in PPMI and 38% of early PD in SPARK met criteria for Stage 2. Currently there is an arbitrary line between prodromal syndrome and newly diagnosed PD/DLB even though these individuals share common molecular pathologic features and similar degree of functional impairment, despite a spectrum of clinical syndromes. The proposed operational definitions for NSD-ISS will aid in identifying individuals with the same biology but varied phenotypic presentations and will help in standardizing terminology and inclusion criteria across studies.

As therapeutic development moves into the earlier stages, NSD-ISS provides a framework to identify and enrich individuals with Stage 2 for earlier interventions--spanning early motor/non-motor manifestations and individuals currently labeled as "prodromal". Baseline heterogeneity can have a substantial negative impact on ability to detect therapeutic effect in interventional trials. Depending on the target population of a biologically targeted therapeutic intervention, enrichment of individuals identified as Stages 2B or 3 may decrease heterogeneity and increase the probability of detecting a meaningful treatment effect. Ultimately, interventions in Stage 0 or 1, prior to onset of any symptoms, will offer ability to test primary disease prevention strategies.

The NSD-ISS delineates Stage 1A versus 1B and Stage 2A versus 2B based on the hypothesis that neuronal synuclein aggregation precedes dopamine system dysfunction. Although there are limited data, results from the SPARK study provide some support for this hypothesis. Among early PD individuals in the SPARK study, 13% met criteria for Stage 2A. These individuals had an abnormal DAT imaging based on visual read but were determined to be D- as their mean putamen SBR was > 75 %ile. Separation between Stage 2A and 2B in our framework is based on the selection of DAT

imaging quantitative cut-off. Future studies may reexamine the cutoff which may impact the distribution of participants in Stage 2. Nevertheless, our results suggest that it is possible to enroll individuals into a clinical trial who are S+D- with subtle clinical signs/symptoms and no functional impairment. More data are necessary to define the timeline of progression from S+D- (Stage 1A) to S+D+ (Stage 1B) and from Stage 1 to 2. The framework enables targeted research in Stage 0 or 1 individuals to elucidate individual biomarker time course and inter-relationship between biomarkers essential for future disease prevention studies.

Our analysis of the time to development of clinically meaningful milestones supports NSD-ISS predictive validity. Individuals in Stage 4 progressed faster than Stage 2B; median time to developing a new milestone was 2.4 years versus 8.3 years. These results suggest that the NSD-ISS may aid in identifying individuals for diagnosis and enrichment in future therapeutic trials. However, these findings also highlight the heterogeneity in clinical and functional impairment even among individuals currently considered to be early PD based on the clinical diagnosis. There are a number of study limitations and future directions as summarized in Panel 2.

In conclusion, we provide the first data-informed application of the NSD definition and the NSD-ISS. Our data strongly support the concept of the biological definition and staging framework. The conceptual framework and operational definitions provide a scaffold to identify scientific questions and define the gaps and opportunities.

We position our anchors as a "pilot demonstration" of the proof of principal and expect that the framework and operational definitions will evolve over time as new data become available. Some potential areas for future iterations include evaluation of additional anchors, including novel and advanced disease-specific markers, non-motor symptoms, and functional anchors. We encourage the field to work collaboratively to explore and develop alternative functional anchors, and work collaboratively to advance the field towards successful therapeutic development to treat this devastating disease.

REFERENCES

1.   Simuni T, Chahine LM, Poston K, et al. A biological definition of neuronal alpha-synuclein disease: towards an integrated staging system for research. *Lancet neurology* 2024; **23**(2): 178-90.
2.   Siderowf A, Concha-Marambio L, Lafontant DE, et al. Assessment of heterogeneity among participants in the Parkinson's Progression Markers Initiative cohort using alpha-synuclein seed amplification: a cross-sectional study. *Lancet neurology* 2023; **22**(5): 407-17.
3.   Postuma RB, Berg D, Stern M, et al. MDS clinical diagnostic criteria for Parkinson's disease. *Mov Disord* 2015; **30**(12): 1591-601.
4.   McKeith IG, Boeve BF, Dickson DW, et al. Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium. *Neurology* 2017; **89**(1): 88-100.
5.   Marek K, Chowdhury S, Siderowf A, et al. The Parkinson's progression markers initiative (PPMI) - establishing a PD biomarker cohort. *Ann Clin Transl Neurol* 2018; **5**(12): 1460-77.
6.   Pagano G, Taylor KI, Anzures-Cabrera J, et al. Trial of Prasinezumab in Early-Stage Parkinson's Disease. *N Engl J Med* 2022; **387**(5): 421-32.
7.   Lang AE, Siderowf AD, Macklin EA, et al. Trial of Cinpanemab in Early Parkinson's Disease. *N Engl J Med* 2022; **387**(5): 408-20.
8.   Brumm MC, Pierz KA, Lafontant DE, et al. Updated Percentiles for the University of Pennsylvania Smell Identification Test in Adults 50 Years of Age and Older. *Neurology* 2023; **100**(16): e1691-e701.
9.   Nasreddine ZS, Phillips NA, Bedirian V, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. *J Am Geriatr Soc* 2005; **53**(4): 695-9.
10.   Goetz CG, Tilley BC, Shaftman SR, et al. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. *Mov Disord* 2008; **23**(15): 2129-70.
11.   Concha-Marambio L, Pritzkow S, Shahnawaz M, Farris CM, Soto C. Seed amplification assay for the detection of pathologic alpha-synuclein aggregates in cerebrospinal fluid. *Nat Protoc* 2023; **18**(4): 1179-96.
12.   Concha-Marambio L, Wang F, Armijo E, et al. Development of a methodology for large-scale production of prions for biological and structural studies. *Front Mol Biosci* 2023; **10**: 1184029.
13.   Concha-Marambio L, Weber S, Farris CM, et al. Accurate Detection of alpha-Synuclein Seeds in Cerebrospinal Fluid from Isolated Rapid Eye Movement Sleep Behavior Disorder and Patients with Parkinson's Disease in the DeNovo Parkinson (DeNoPa) Cohort. *Mov Disord* 2023; **38**(4): 567-78.
14.   Concha-Marambio L, Farris CM, Holguin B, et al. Seed Amplification Assay to Diagnose Early Parkinson's and Predict Dopaminergic Deficit Progression. *Mov Disord* 2021; **36**(10): 2444-6.
15.   Seibyl JP, Marek K, Sheff K, et al. Iodine-123-beta-CIT and iodine-123-FPCIT SPECT measurement of dopamine transporters in healthy subjects and Parkinson's patients. *J Nucl Med* 1998; **39**(9): 1500-8.
16.   Brumm MC, Siderowf A, Simuni T, et al. Parkinson's Progression Markers Initiative: A Milestone-Based Strategy to Monitor Parkinson's Disease Progression. *J Parkinsons Dis* 2023; **13**(6): 899-916.

SOURCES OF FUNDING:

Funding support for the data analysis was provided by The Michael J. Fox Foundation for Parkinson's Research (MJFF).

This report presents data from three studies, including PASADENA, supported by F. Hoffman-La Roche and Prothena Biosciences, SPARK, supported by Biogen, and PPMI. PPMI – a public-private partnership – is funded by MJFF and funding partners, including 4D Pharma, Abbvie, AcureX, Allergan, Amathus Therapeutics, Aligning Science Across Parkinson's, AskBio, Avid Radiopharmaceuticals, BIAL, BioArctic, Biogen, Biohaven, BioLegend, BlueRock Therapeutics, BristolMyers Squibb, Calico Labs, Capsida Biotherapeutics, Celgene, Cerevel Therapeutics, Coave Therapeutics, DaCapo Brainscience, Denali, Edmond J. Safra Foundation, Eli Lilly, Gain Therapeutics, GE HealthCare, Genentech, GSK, Golub Capital, Handl Therapeutics, Insitro, Janssen Neuroscience, Jazz Pharmaceuticals, Lundbeck, Merck, Meso Scale Discovery, Mission Therapeutics, Neurocrine Biosciences, Neuropore, Pfizer, Piramal, Prevail Therapeutics, Roche, Sanofi, Servier, Sun Pharma Advanced Research Company, Takeda, Teva, UCB, Vanqua Bio, Verily, Voyager Therapeutics, the Weston Family Foundation and Yumanity Therapeutics.

DATA SOURCE:

PPMI data used in the preparation of this article were obtained June 12, 2023 from the Parkinson's Progression Markers Initiative (PPMI) database (www.ppmi-info.org/access-data-specimens/download-data), RRID:SCR 006431. For up-to-date information on the study, visit www.ppmi-info.org.

DATA AVAILABILITY:

PPMI data are publicly available from the Parkinson's Progression Markers Initiative (PPMI) database (www.ppmi-info.org/access-data-specimens/download-data), RRID:SCR 006431. For up-to-date information on the study, visit www.ppmi-info.org. Use of Tier 4 data: This analysis was conducted by the PPMI Statistics Core and used actual dates of activity for participants, a restricted data element not available to public users of PPMI data

For PASADENA, qualified researchers may request access to individual patient level clinical data through a data request platform. At the time of writing, this request platform is Vivli. https://vivli.org/ourmember/roche/. Further details on Roche's criteria for eligible trials for data access are available here (https://vivli.org/members/ourmembers/). For up-to-date details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here: https://go.roche.com/data_sharing. Anonymized records for individual patients across more than one data source external to Roche cannot, and should not, be linked due to a potential increase in risk of patient re-identification.

For SPARK, to request access to data, please visits http://www.biogenclinicaldatarequest.com. The individual participant data collected during the trial, which supports the research proposal, will be available to qualified researchers after anonymization and upon approval of the research proposal. Anonymization of the datasets is necessary to allow data to be shared ethically and legally, and to maximize their significant social, environmental, and economic value, whilst preserving confidentiality of the individuals who participated in studies conducted by Biogen.

ACKNOWLEDGEMENT:

We appreciate Dr. Teresa Buraccio for critical review of the draft of the manuscript.

We thank the SPARK investigators, trial coordinators, staff, and participants for their contribution to the trial. We appreciate Dr. Minhua Yang for analyses of the SPARK data.

We thank the PASADENA investigators, trial coordinators, staff, and participants for their contribution to the trial. We appreciate Drs. Thomas Riorge and Annabelle Monnet for analyses of the PASADENA data.

Panel 1: Glossary of terms

Neuronal α-synuclein (n-asyn)
Disease-defining form of a-synuclein: misfolded, pathological, predominantly neuronal a-synuclein

Neuronal α-synuclein disease (NSD)
Disease defined by presence of n-asyn and dopaminergic dysfunction or presence of a fully penetrant *SNCA* variant; disease is defined independent of presence of clinical signs and symptoms

S anchor for neuronal α-synuclein disease (S)
Indicates presence (S+) or absence (S-) of n-asyn as measured by any validated biomarker of n-asyn pathology

D anchor for neuronal α-synuclein disease (D)
Indicates presence (D+ or absence (D-) of dopaminergic dysfunction as measured by any validated biomarker of dopaminergic dysfunction

Genetic status (G)
Indicates presence (G+) or absences (G-) of relevant pathogenic variants

α-synuclein seed amplification assay (SAA)
An assay that leverages the self-replicating properties of misfolded a-synuclein by means of fragmentation and elongation cycles

Not evaluable
CSF samples not available for n-asyn SAA

Evaluable
CSF samples analyzed for n-asyn SAA and results available

Not stageable
Missing dopamine transporter or clinical data and unable to assess stages

Not Neuronal a-synuclein disease (Not NSD)
Disease defined by absence of n-asyn

Panel 2: Limitations

- Ascertainment of S+ status is required to select participants for a-syn targeting therapeutic trials today. Important feasibility and scalability limitations are acknowledged and matrixes for n-asyn testing will soon transition from CSF to more accessible tissues or fluids (skin, blood) in the near future. In the interim, while not a substitute for biological characterization, a readily accessible assessment of hyposmia may significantly reduce the number of S- individuals in these trials.
- Stage 1. Additional datasets and longitudinal follow-up of PPMI prodromal and non-manifesting genetic cohorts are necessary to further inform the temporal relationship between S and D positivity, as well as whether progression through the stages is sequential
- Transition from stage 1 to stage 2. Better delineation of the spectrum of the clinical features that signify stage 2 will inform the field.
- Transition to stage 3 is currently defined by functional impairment in either cognitive or motor domains; a path for the non-motor domain was not included due to lack of specificity of the anchors. More data to define such a path will be necessary. Future NSD-ISS iterations may consider operationalizing additional non-motor signs/symptoms such as constipation, dysautonomia, and disease-related depression and anxiety, potentially drawing from other MDS-UPDRS-I items.
- Our selection of the anchors for Stage 3-6 was pragmatic and limited by the available measures from included studies. Additional operational definitions and analyses may be considered, such as alternative available clinical and functional scales (i.e., PDQ-39, Non-Motor Symptoms Scale, or Schwab and England Activities of Daily Living) and/or refinement of cut-offs to delineate stages. We envision that the field will require development of novel patient-centered sensitive measures of functional impairment.

Figure 1. Participant Flowchart

¹Not evaluable = CSF samples not available for alpha-synuclein aggregation testing
²Evaluable = CSF samples analyzed for alpha-synuclein aggregation and results available
³NSD = Individuals with positive alpha-synuclein aggregation tests (S+)
⁴Not stageable = Missing DaT-SPECT or clinical data and unable to assess stages
⁵Not NSD = Individuals with negative alpha-synuclein aggregation tests (S-)
NSD= Neuronal Synuclein Disease

Table 1. Staging anchors for application of the NSD-ISS

Stage		Biologic anchors		Anchors of clinical signs or symptoms (stages 2A and 2B) and functional impairment (stages 3-6)[1, 2]	
Stage	**S**	**D** [a]	**G**	**Domain**	**Anchor(s)**
Stage 0	-	-	*SNCA* [b]	—	—
Stage 1A	+	-	±	(1) Cognitive	(1) MDS-UPDRS item 1.1 = 0; and
Stage 1B	+	+	±	(2) Motor	(2a) Does not have subthreshold parkinsonism [c]; and (2b) is not on PD meds; and
				(3) Other non-motor	(3a) Does not have RBD; and (3b) is not hyposmic [d]
Stage 2A	+	-	±	(1) Cognitive	(1) Item 1.1 = 1 AND MoCA ≥ 25; or
Stage 2B	+	+	±	(2) Motor	(2a) Has subthreshold parkinsonism [c]; or (2b) is on PD meds; or
				(3) Other non-motor	(3a) Has RBD; or (3b) is hyposmic [d]
Stage 3	+	+	±	(1) Cognitive	(1a) Item 1.1 = 1 AND MoCA ≤ 24; or (1b) Item 1.1 = 2 AND MoCA ≥ 25; or
				(2) Motor	(2) MDS-UPDRS-II = 3-13 AND either subthreshold parkinsonism [c] or PD meds
Stage 4	+	+	±	(1) Cognitive	(1a) Item 1.1 = 2 and MoCA ≤ 24; or (1b) item 1.1 = 3 AND MoCA ≥ 25; or
				(2) Motor	(2) MDS-UPDRS-II = 14-26; or
				(3) Other non-motor	(3) MDS-UPDRS-I (excluding item 1.1) = 13-24 [e]
Stage 5	+	+	±	(1) Cognitive	(1a) Item 1.1 = 3 AND MoCA ≤ 24; or (1b) item 1.1 = 4 AND MoCA ≥ 25; or
				(2) Motor	(2) MDS-UPDRS-II = 27-39; or
				(3) Other non-motor	(3) MDS-UPDRS-I (excluding item 1.1) = 25-36
Stage 6	+	+	±	(1) Cognitive	(1) Item 1.1 = 4 AND MoCA ≤ 24; or
				(2) Motor	(2) MDS-UPDRS-II ≥ 40; or
				(3) Other non-motor	(3) MDS-UPDRS-I (excluding item 1.1) ≥ 37

[1] Presence of qualifying signs/ symptoms in any single domain qualifies for stage 2 but individuals can have combination in all 3 domains.

[2] Presence of qualifying functional impairment in any single domain qualifies for stage 3-6 but individuals can have combination in all 3 domains.

[a] D positivity defined as < 75% age/sex-expected lowest putamen SBR.

[b] Only fully penetrant pathogenic *SNCA* variants qualify for Stage 0.

[c] Subthreshold parkinsonism defined as MDS-UPDRS-III ≥ 5 excluding postural and action tremor.

[d] Hyposmia defined as UPSIT percentile ≤ 15 (age and sex adjusted).

[e] MDS-UPDRS-I (excluding item 1.1) ≥ 13 is sufficient for stage 4 provided that stage 2 criteria are met.

MDS-UPDRS=Movement Disorder Society Unified Parkinson's Disease Rating Scale. MoCA=Montreal Cognitive Assessment. NSD=Neuronal Synuclein Disease. PD=Parkinson's disease. RBD=REM sleep behavior disorder. UPSIT= University of Pennsylvania Smell Identification Test

Table 2. Baseline demographic characteristics of NSD participants by study

NSD	PPMI (cohort at enrollment)											PASADENA	SPARK
	Sporadic PD (N = 507)	LRRK2 PD (N = 87)	GBA PD (N = 56)	SNCA PD (N = 9)	PRKN PD (N = 2)	RBD (N = 61)	Hyposmia (N = 40)	LRRK2 NMC (N = 12)	GBA NMC (N = 11)	SNCA NMC (N = 3)	HC (N = 15)	Early PD (N = 61)	Early PD (N = 110)
Age (Years), Mean (SD)	62.4 (9.2)	60.1 (8.8)	60.7 (10.3)	46.3 (8.9)	70.0 (12.4)	69.8 (5.4)	67.5 (5.1)	66.9 (8.9)	63.3 (6.1)	43.6 (1.4)	67.2 (8.4)	60.2 (9.8)	61.1 (8.2)
Sex, n (%)													
Male	336 (66%)	52 (60%)	36 (64%)	4 (44%)	2 (100%)	47 (77%)	20 (50%)	8 (67%)	5 (45%)	0	10 (67%)	42 (69%)	71 (64.5)
Female	171 (34%)	35 (40%)	20 (36%)	5 (56%)	0	14 (23%)	20 (50%)	4 (33%)	6 (55%)	3 (100%)	5 (33%)	19 (31%)	39 (35.5)
Years Since PD Diagnosis, Mean (SD)	0.7 (0.6)	3.0 (2.2)	2.6 (2.4)	3.0 (2.2)	0.3 (0.0)	NA	NA	NA	NA	NA	NA	0.9 (0.5)	0.6 (0.6)
MDS-UPDRS Item 1.1 Score, n (%)													
0: Normal	378 (75%)	58 (67%)	36 (64%)	5 (56%)	2 (100%)	36 (59%)	28 (70%)	8 (67%)	9 (82%)	3 (100%)	15 (100%)	48 (79%)	98 (89%)
1: Slight	116 (23%)	24 (28%)	18 (32%)	3 (33%)	0	19 (31%)	12 (30%)	4 (33%)	2 (18%)	0	0	9 (15%)	8 (7%)
2 - 4: Mild to Severe	13 (3%)	5 (6%)	2 (4%)	1 (11%)	0	6 (10%)	0	0	0	0	0	4 (7%)	4 (4%)
MDS-UPDRS Part I, Mean (SD)	5.6 (4.1)	8.2 (5.7)	8.4 (5.0)	9.1 (5.3)	4.5 (3.5)	7.9 (4.4)	5.0 (3.6)	3.9 (3.8)	5.8 (6.0)	3.7 (3.8)	3.0 (1.8)	4.6 (4.0)	4.0 (3.8)
MDS-UPDRS Part II, Mean (SD)	5.7 (4.2)	7.8 (6.0)	8.5 (5.8)	9.9 (5.2)	2.5 (0.7)	2.2 (2.8)	1.7 (2.4)	0.9 (1.2)	2.2 (4.4)	0.0 (0.0)	0.3 (0.6)	5.0 (3.6)	4.8 (3.6)
MDS-UPDRS Part III (OFF), Mean (SD)	21.4 (8.9)	23.9 (12.0)	27.3 (11.1)	14.9 (10.7)	9.5 (0.7)	4.6 (3.7)	2.8 (3.4)	2.8 (4.6)	2.9 (4.9)	0.0 (0.0)	1.0 (2.0)	22.6 (9.2)	23.7 (8.9)
Missing	1	19	5	0	0	0	0	0	0	0	0	0	0
Subthreshold Parkinsonism*, n (%)	505 (99.8%)	67 (99%)	51 (100%)	9 (100%)	2 (100%)	17 (28%)	6 (15%)	2 (17%)	2 (18%)	0	0	59 (97%)	110 (100%)
MOCA Total Score, Mean (SD)	27.0 (2.4)	26.9 (2.6)	26.5 (2.2)	25.1 (6.4)	28.5 (0.7)	26.3 (3.7)	26.6 (2.2)	26.1 (3.0)	27.3 (2.2)	26.7 (2.3)	27.7 (1.8)	28.1 (1.8)	27.6 (1.7)
On PD Treatment, n (%)	0	71 (82%)	42 (75%)	8 (89%)	0	0	0	0	0	0	0	60 (98%)[1]	0
UPSIT Percentile ≤ 15, n (%)	406 (82%)	63 (76%)	53 (96%)	9 (100%)	2 (100%)	58 (97%)	40 (100%)	3 (25%)	6 (55%)	3 (100%)	9 (60%)	NA	NA
Age/Sex-Expected Lowest Putamen SBR <75%, n (%)	505 (99.6%)	87 (100%)	56 (100%)	9 (100%)	2 (100%)	42 (69%)	30 (75%)	5 (42%)	1 (9%)	0	1 (7%)	61 (100%)	96 (87%)
Hoehn and Yahr Stage, n (%)													
0: Asymptomatic	0	0	0	0	0	NA	NA	NA	NA	NA	NA	NA	0
1: Unilateral Involvement only	198 (39%)	17 (25%)	15 (31%)	4 (44%)	2 (100%)	NA	NA	NA	NA	NA	NA	NA	40 (36%)
2: Bilateral Involvement without impairment of balance	309 (61%)	47 (69%)	32 (65%)	4 (44%)	0	NA	NA	NA	NA	NA	NA	NA	65 (59%)
3: Mild to Moderate Involvement	0	4 (6%)	2 (4%)	1 (11%)	0	NA	NA	NA	NA	NA	NA	NA	2 (2%)
Missing	0	19	7	0	0	NA	NA	NA	NA	NA	NA	NA	3 (3%)

One sporadic PD participant was missing a score for MDS-UPDRS Part I. Three sporadic PD and one LRRK2 PD participants were missing a MoCA score.
Ten sporadic PD, 4 LRRK2 PD, 1 GBA PD, and 1 RBD participant were missing an UPSIT score.* MDS-UPDRS Part III > 4 excluding postural and action tremor.
HC= Healthy controls. MDS-UPDRS=Movement Disorder Society Unified Parkinson's Disease Rating Scale. MoCA=Montreal Cognitive Assessment. NMC=non-manifesting carriers. PD=Parkinson's disease. RBD=REM sleep behavior disorder. SBR= Striatal Binding Ratio. UPSIT= University of Pennsylvania Smell Identification Test
[1]Participants in PASADENA study were allowed to be on a stable dose of monoamine oxidase inhibitors B (MAO-B) at enrollment.

Table 3. Baseline staging of NSD participants in the PPMI, PASADENA, and SPARK studies

Variable	PPMI (cohort at enrollment)											PASADENA	SPARK
	Sporadic PD (N = 507)	LRRK2 PD (N = 87)	GBA PD (N = 56)	SNCA PD (N = 9)	PRKN PD (N = 2)	RBD (N = 61)	Hyposmia (N = 40)	LRRK2 NMC (N = 12)	GBA NMC (N = 11)	SNCA NMC (N = 3)	HC (N = 15)	Early PD (N = 61)	Early PD (N = 110)
Stage, n (%)													
0	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	3 (100%)	N/A	NA	NA
1A	0	0	0	0	0	0	0	3 (25%)	4 (36%)	0	6 (40%)	0	0
1B	0	0	0	0	0	0	0	3 (25%)	0	0	0	0	0
2A	2 (<1%)	0	0	0	0	19 (31%)	10 (25%)	4 (33%)	6 (55%)	0	8 (53%)	0	14 (13%)
2B	126 (25%)	10 (11%)	7 (13%)	1 (11%)	1 (50%)	30 (49%)	25 (63%)	2 (17%)	0	0	1 (7%)	16 (26%)	28 (25%)
3	328 (65%)	53 (61%)	33 (59%)	3 (33%)	1 (50%)	5 (8%)	4 (10%)	0	1 (9%)	0	0	40 (66%)	61 (55%)
4	50 (10%)	22 (25%)	15 (27%)	4 (44%)	0	6 (10%)	1 (3%)	0	0	0	0	5 (8%)	7 (6%)
5	1 (<1%)	1 (1%)	1 (2%)	1 (11%)	0	1 (2%)	0	0	0	0	0	0	0
6	0	1 (1%)	0	0	0	0	0	0	0	0	0	0	0

HC= Healthy controls. NMC=non-manifesting carriers. PD=Parkinson's disease. RBD=REM sleep behavior disorder

Figure 2. Time to reaching any progression milestone by stage at baseline among PPMI sporadic PD cohort

Supplement Figure 1. Proportion in each NSD stage in PPMI vs. PASADENA vs. SPARK

Stage	PPMI Sporadic PD (N=507)	PASADENA Confirmed S+ (N=61)	SPARK Confirmed S+ (N=110)
Stage 2A	2 (<1%)	0	14 (13%)
Stage 2B	126 (25%)	16 (26%)	28 (25%)
Stage 3	328 (65%)	40 (66%)	61 (55%)
Stage 4	50 (10%)	5 (8%)	7 (6%)
Stage 5	1 (<1%)	0	0

Supplement Table 1. Proposed neuronal α-synuclein disease integrated staging system

		a-synuclein Biomarker (S)	Dopamine Dysfunction Biomarker (D)	Clinical signs and symptoms attributable to neuronal a-synuclein disease syndromes	Functional impairment attributable to neuronal a-synuclein disease syndromes
Genetic Risk					
R^L	(G) Genetic risk variants – low age adjusted risk (constantly redefined).	Absent	Absent	No clinical signs or symptoms	No functional impairment
R^H	(G) Genetic risk variants – high age adjusted risk (constantly redefined)	Absent	Absent	No clinical signs or symptoms	No functional impairment
Stage Definition					
0	Fully penetrant *SNCA* variant (G+)	S-	D-	No clinical signs or symptoms	No functional impairment
1A	Characteristic pathological changes, but no evidence of clinical signs or symptoms	S+	D-	No clinical signs or symptoms	No functional impairment
1B	Characteristic pathologic changes plus dopaminergic dysfunction, but no evidence of clinical signs or symptoms	S+	D+	No clinical signs or symptoms	No functional impairment
2A	Characteristic pathological changes and subtle detectable clinical signs and symptoms, but no functional impairment.	S+	D-	Subtle clinical signs or symptoms; can be motor or non-motor: hyposmia, RBD, cognitive abnormalities, constipation, dysautonomia, depression, anxiety.	No functional impairment
2B	Characteristic pathologic changes plus dopaminergic dysfunction and subtle detectable clinical signs and symptoms, but no functional impairment.	S+	D+	Subtle clinical signs or symptoms; can be motor or non-motor: hyposmia, RBD, cognitive abnormalities, constipation, dysautonomia, depression, anxiety.	No functional impairment
3	Characteristic pathologic changes plus dopaminergic dysfunction and clinical signs and symptoms causing slight functional impairment.	S+	D+	Relevant motor and non-motor signs and symptoms increasing in severity, but stage is defined by a slight degree of functional impairment	Slight: functional impairment with minimal impact on complex tasks of daily life and usual activities, such as finances, transportation, food, household, conversation
4	Characteristic pathologic changes plus dopaminergic dysfunction and clinical signs and symptoms causing mild functional impairment.	S+	D+	Relevant motor and non-motor signs and symptoms increasing in severity, but stage is defined by a mild degree of functional impairment	Mild: functional impairment severe enough to cause some impairment in complex tasks of daily life and usual activities, but basic tasks of daily life related to personal care are intact, such as bathing, dressing, walking, using the toilet, eating
5	Characteristic pathologic changes plus dopaminergic dysfunction and clinical signs and symptoms causing moderate functional impairment.	S+	D+	Relevant motor and non-motor signs and symptoms increasing in severity, but stage is defined by a moderate degree of functional impairment	Moderate: functional impairment severe enough to require assistance with basic tasks of daily life
6	Characteristic pathologic changes plus dopaminergic dysfunction and clinical signs and symptoms causing severe functional impairment	+	+	Relevant motor and non-motor signs and symptoms increasing in severity, but stage is defined by a severe degree of functional impairment	Severe: functional impairment severe enough to require dependence on others for basic tasks of daily life

Supplement Table 2. Baseline demographic characteristics of Not NSD participants by cohort

NSD	PPMI (cohort at enrollment)											PASADENA	SPARK
	Sporadic PD (N = 36)	LRRK2 PD (N = 55)	GBA PD (N = 5)	SNCA PD (N = 0)	PRKN PD (N = 4)	RBD (N = 19)	Hyposmia (N = 16)	LRRK2 NMC (N = 182)	GBA NMC (N = 170)	SNCA NMC (N = 0)	HC (N = 207)	Early PD (N = 6)	Early PD (N = 11)
Age (Years), Mean (SD)	65.7 (10.9)	68.3 (6.7)	62.1 (10.7)	NA	43.8 (14.2)	66.6 (7.1)	68.4 (6.5)	61.3 (7.5)	62.0 (6.8)	NA	61.1 (11.7)	NA	57.6 (57.7)
Sex, n (%)													
Male	21 (58%)	20 (36%)	2 (40%)	NA	3 (75%)	16 (84%)	6 (38%)	75 (41%)	69 (41%)	NA	129 (62%)	NA	6 (55%)
Female	15 (42%)	35 (64%)	3 (60%)	NA	1 (25%)	3 (16%)	10 (63%)	107 (59%)	101 (59%)	NA	78 (38%)	NA	5 (46%)
Years Since PD Diagnosis, Mean (SD)	0.5 (0.4)	2.8 (2.1)	1.7 (2.1)	NA	6.6 (2.9)	NA	NA	NA	NA	NA	NA	NA	1.0 (0.8)
MDS-UPDRS Item 1.1 Score, n (%)													
0: Normal	29 (81%)	39 (71%)	3 (60%)	NA	4 (100%)	12 (63%)	12 (75%)	157 (87%)	137 (81%)	NA	189 (92%)	NA	9 (82%)
1: Slight	4 (11%)	15 (27%)	2 (40%)	NA	0	7 (37%)	4 (25%)	21 (12%)	27 (16%)	NA	16 (8%)	NA	2 (18%)
2 - 4: Mild to Severe	3 (8%)	1 (2%)	0	NA	0	0	0	3 (2%)	6 (4%)	NA	1 (<1%)	NA	0
Missing	0	0	0	NA	0	0	0	1	0	NA	1	NA	0
MDS-UPDRS Part I, Mean (SD)	7.2 (5.6)	7.3 (6.2)	7.4 (7.1)	NA	6.0 (3.6)	7.2 (5.5)	5.4 (4.6)	4.4 (3.6)	5.6 (4.7)	NA	3.0 (2.9)	NA	4.3 (3.3)
Missing	0	0	0	NA	0	0	0	1	0	NA	1	NA	0
MDS-UPDRS Part II, Mean (SD)	7.4 (4.7)	5.7 (4.9)	6.8 (4.4)	NA	5.0 (3.2)	1.7 (2.3)	1.4 (1.5)	1.0 (1.9)	1.2 (2.2)	NA	0.4 (0.9)	NA	4.7 (3.9)
Missing	0	0	0	NA	0	0	0	1	0	NA	1	NA	0
MDS-UPDRS Part III (OFF), Mean (SD)	22.8 (7.1)	18.1 (8.0)	24.8 (10.9)	NA	16.0 (NA)	5.4 (3.9)	4.2 (4.0)	3.0 (3.9)	2.4 (3.5)	NA	1.3 (2.2)	NA	22.1 (9.3)
Missing	0	9	1	NA	3	1	1	3	1	NA	3	NA	0
Subthreshold Parkinsonism*, n (%)	36 (100%)	45 (98%)	4 (100%)	NA	1 (100%)	8 (44%)	7 (47%)	29 (16%)	23 (14%)	NA	12 (6%)	NA	11 (100%)
Missing	0	9	1	NA	3	1	1	3	1	NA	3	NA	0
MOCA Total Score, Mean (SD)	26.9 (2.1)	25.2 (3.2)	27.0 (2.0)	NA	27.5 (2.4)	26.6 (3.1)	27.0 (1.9)	26.8 (2.5)	26.7 (2.3)	NA	28.0 (1.5)	NA	26.3 (2.1)
Missing	0	0	0	NA	0	0	0	1	0	NA	0	NA	0
On PD Treatment, n (%)	0	36 (65%)	2 (40%)	NA	0	0	0	0	1 (1%)	NA	0	NA	0
Missing	0	0	0	NA	0	1	0	3	0	NA	3	NA	0
UPSIT Percentile ≤ 15, n (%)	5 (15%)	13 (25%)	0	NA	2 (50%)	4 (21%)	15 (94%)	24 (13%)	15 (9%)	NA	21 (10%)	NA	NA
Missing	2	2	0	NA	0	0	0	1	0	NA	2	NA	NA
Age/Sex-Expected Lowest Putamen SBR <75%, n (%)	32 (91%)	48 (98%)	5 (100%)	NA	4 (100%)	8 (42%)	6 (38%)	30 (17%)	8 (5%)	NA	28 (14%)	NA	6 (55%)
Missing	1	6	0	NA	0	0	0	5	5	NA	3	NA	0

NSD	PPMI (cohort at enrollment)											PASADENA	SPARK
	Sporadic PD (N = 36)	LRRK2 PD (N = 55)	GBA PD (N = 5)	SNCA PD (N = 0)	PRKN PD (N = 4)	RBD (N = 19)	Hyposmia (N = 16)	LRRK2 NMC (N = 182)	GBA NMC (N = 170)	SNCA NMC (N = 0)	HC (N = 207)	Early PD (N = 6)	Early PD (N = 11)
Hoehn and Yahr Stage, n (%)													
0: Asymptomatic	0	0	0	NA	0	NA	NA	NA	NA	NA	NA	NA	0
1: Unilateral Involvement only	5 (14%)	12 (26%)	1 (25%)	NA	0	NA	NA	NA	NA	NA	NA	NA	2 (18%)
2: Bilateral Involvement without impairment of balance	31 (86%)	29 (63%)	3 (75%)	NA	1 (100%)	NA	NA	NA	NA	NA	NA	NA	9 (82%)
3: Mild to moderate involvement	0	5 (11%)	0	NA	0	NA	NA	NA	NA	NA	NA	NA	0
Missing	0	9	1	NA	3	NA	NA	NA	NA	NA	NA	NA	0

* MDS-UPDRS Part III > 4 excluding postural and action tremor.

HC= Healthy controls. MDS-UPDRS=Movement Disorder Society Unified Parkinson's Disease Rating Scale. MoCA=Montreal Cognitive Assessment. NMC=non-manifesting carriers. PD=Parkinson's disease. RBD=REM sleep behavior disorder. SBR= Striatal Binding Ratio. UPSIT= University of Pennsylvania Smell Identification Test

Supplement Table 3a. Baseline demographic characteristics of Not Evaluable participants by cohort

NSD	PPMI (cohort at enrollment)											PASADENA	SPARK
	Sporadic PD (N = 252)	LRRK2 PD (N = 20)	GBA PD (N = 30)	SNCA PD (N = 0)	PRKN PD (N = 4)	RBD (N = 133)	Hyposmia (N = 256)	LRRK2 NMC (N = 12)	GBA NMC (N = 9)	SNCA NMC (N = 0)	HC (N = 38)	Early PD (N = 249)	Early PD (N = 236)
Age (Years), Mean (SD)	64.2 (9.5)	68.4 (10.3)	62.3 (11.6)	NA	51.5 (10.9)	68.4 (5.4)	67.6 (5.7)	63.2 (7.7)	58.9 (8.8)	NA	61.0 (11.3)	NA	59.7 (9.4)
Missing	0	0	0	NA	0	0	1	0	0	NA	0	NA	0
Sex, n (%)													
Male	164 (65%)	5 (25%)	12 (40%)	NA	3 (75%)	107 (80%)	101 (40%)	4 (33%)	2 (22%)	NA	23 (61%)	NA	173 (73%)
Female	88 (35%)	15 (75%)	18 (60%)	NA	1 (25%)	26 (20%)	154 (60%)	8 (67%)	7 (78%)	NA	15 (39%)	NA	63 (27%)
Missing	0	0	0	NA	0	0	1	0	0	NA	0	NA	0
Years Since PD Diagnosis, Mean (SD)	0.8 (0.6)	3.3 (2.0)	3.5 (2.2)	NA	5.7 (5.3)	NA	NA	NA	NA	NA	NA	NA	0.7 (0.7)
Missing	1	0	0	NA	0	NA	NA	NA	NA	NA	NA	NA	0
MDS-UPDRS Item 1.1 Score, n (%)													
0: Normal	167 (66%)	11 (55%)	22 (73%)	NA	3 (75%)	81 (62%)	185 (73%)	6 (50%)	7 (78%)	NA	34 (92%)	NA	195 (83%)
1: Slight	71 (28%)	7 (35%)	4 (13%)	NA	0	35 (27%)	58 (23%)	6 (50%)	2 (22%)	NA	2 (5%)	NA	41 (17%)
2 - 4: Mild to Severe	14 (6%)	2 (10%)	4 (13%)	NA	1 (25%)	15 (11%)	11 (4%)	0	0	NA	1 (3%)	NA	0
Missing	0	0	0	NA	0	2	2	0	0	NA	1	NA	0
MDS-UPDRS Part I, Mean (SD)	6.4 (4.8)	8.8 (5.6)	7.4 (5.0)	NA	5.5 (4.4)	7.6 (5.9)	6.0 (4.6)	7.0 (4.7)	9.0 (9.3)	NA	3.5 (3.2)	NA	4.4 (3.5)
Missing	6	0	0	NA	0	3	7	0	0	NA	1	NA	0
MDS-UPDRS Part II, Mean (SD)	6.9 (4.9)	6.6 (5.8)	7.3 (6.2)	NA	5.3 (4.6)	2.5 (3.5)	2.1 (3.7)	2.4 (4.5)	3.4 (7.6)	NA	0.5 (1.1)	NA	5.6 (3.9)
Missing	2	0	0	NA	0	2	3	0	0	NA	1	NA	0
MDS-UPDRS Part III (OFF), Mean (SD)	25.0 (11.5)	23.1 (8.7)	22.5 (8.7)	NA	15.5 (5.3)	4.2 (4.3)	4.1 (4.8)	3.3 (3.0)	5.6 (8.8)	NA	1.6 (1.9)	NA	22.3 (9.0)
Missing	1	7	11	NA	0	2	16	0	1	NA	2	NA	0
Subthreshold Parkinsonism*, n (%)	249 (99%)	13 (100%)	19 (100%)	NA	4 (100%)	33 (25%)	58 (24%)	2 (17%)	2 (25%)	NA	3 (8%)	NA	235 (100%)
Missing	1	7	11	NA	0	2	16	0	1	NA	2	NA	0
MOCA Total Score, Mean (SD)	26.7 (2.3)	24.6 (4.0)	26.3 (3.7)	NA	25.5 (3.7)	26.1 (2.9)	26.9 (2.2)	26.2 (2.7)	26.7 (2.7)	NA	27.8 (1.6)	NA	27.4 (2.0)
Missing	3	1	0	NA	0	1	5	0	0	NA	0	NA	0
On PD Treatment, n (%)	0	14 (70%)	21 (70%)	NA	1 (25%)	1 (1%)	0	0	0	NA	0	NA	0
Missing	1	0	0	NA	0	2	6	0	1	NA	1	NA	0
UPSIT Percentile ≤ 15, n (%)	215 (88%)	8 (47%)	19 (70%)	NA	3 (75%)	96 (74%)	254 (99.6%)	3 (25%)	2 (25%)	NA	14 (40%)	NA	NA
Missing	7	3	3	NA	0	3	1	0	1	NA	3	NA	NA
Age/Sex-Expected Lowest Putamen SBR <75%, n (%)	240 (98%)	14 (100%)	17 (94%)	NA	4 (100%)	52 (40%)	122 (48%)	2 (18%)	0	NA	1 (3%)	NA	215 (91%)

NSD	PPMI (cohort at enrollment)											PASADENA	SPARK
	Sporadic PD (N = 252)	LRRK2 PD (N = 20)	GBA PD (N = 30)	SNCA PD (N = 0)	PRKN PD (N = 4)	RBD (N = 133)	Hyposmia (N = 256)	LRRK2 NMC (N = 12)	GBA NMC (N = 9)	SNCA NMC (N = 0)	HC (N = 38)	Early PD (N = 249)	Early PD (N = 236)
Missing	8	6	12	NA	0	2	1	1	0	NA	5	NA	0
Hoehn and Yahr Stage, n (%)													
0: Asymptomatic	0	0	0	NA	0	NA	NA	NA	NA	NA	NA	NA	0
1: Unilateral Involvement only	74 (29%)	2 (15%)	6 (32%)	NA	1 (25%)	NA	NA	NA	NA	NA	NA	NA	56 (24%)
2: Bilateral Involvement without impairment of balance	173 (69%)	10 (77%)	11 (58%)	NA	3 (75%)	NA	NA	NA	NA	NA	NA	NA	164 (70%)
3: Mild to Moderate Involvement	4 (2%)	1 (8%)	2 (11%)	NA	0	NA	NA	NA	NA	NA	NA	NA	2 (1%)
Missing	1	7	11	NA	0	NA	NA	NA	NA	NA	NA	NA	14 (6%)

* MDS-UPDRS Part III > 4 excluding postural and action tremor.

HC= Healthy controls. MDS-UPDRS=Movement Disorder Society Unified Parkinson's Disease Rating Scale. MoCA=Montreal Cognitive Assessment. NMC=non-manifesting carriers. PD=Parkinson's disease. RBD=REM sleep behavior disorder. SBR= Striatal Binding Ratio. UPSIT= University of Pennsylvania Smell Identification Test

Supplement Table 3b. Baseline demographic characteristics of NSD and Not Stageable participants by cohort

NSD	PPMI (cohort at enrollment)											PASADENA	SPARK
	Sporadic PD (N = 5)	LRRK2 PD (N = 10)	GBA PD (N = 9)	SNCA PD (N = 20)	PRKN PD (N = 0)	RBD (N = 0)	Hyposmia (N = 1)	LRRK2 NMC (N = 4)	GBA NMC (N = 0)	SNCA NMC (N = 7)	HC (N = 0)	Early PD (N = 0)	Early PD (N = 0)
Age (Years), Mean (SD)	70.1 (9.0)	63.2 (6.0)	64.5 (8.7)	51.6 (10.9)	NA	NA	68.5 (NA)	61.5 (10.9)	NA	43.9 (15.4)	NA	NA	NA
Sex, n (%)													
Male	2 (40%)	5 (50%)	4 (44%)	9 (45%)	NA	NA	1 (100%)	1 (25%)	NA	1 (14%)	NA	NA	NA
Female	3 (60%)	5 (50%)	5 (56%)	11 (55%)	NA	NA	0	3 (75%)	NA	6 (86%)	NA	NA	NA
Years Since PD Diagnosis, Mean (SD)	0.8 (0.6)	3.3 (1.8)	4.2 (2.1)	3.5 (3.2)	NA	NA	NA	NA	NA	NA	NA	NA	NA
MDS-UPDRS Item 1.1 Score, n (%)													
0: Normal	4 (80%)	6 (75%)	8 (89%)	14 (70%)	NA	NA	1 (100%)	3 (75%)	NA	6 (86%)	NA	NA	NA
1: Slight	1 (20%)	2 (25%)	1 (11%)	4 (20%)	NA	NA	0	1 (25%)	NA	1 (14%)	NA	NA	NA
2 - 4: Mild to Severe	0	0	0	2 (10%)	NA	NA	0	0	NA	0	NA	NA	NA
Missing	0	2	0	0	NA	NA	0	0	NA	0	NA	NA	NA
MDS-UPDRS Part I, Mean (SD)	14.5 (0.7)	6.0 (3.6)	4.8 (3.6)	9.3 (6.6)	NA	NA	-	4.0 (2.7)	NA	3.0 (2.3)	NA	NA	NA
Missing	3	2	0	0	NA	NA	1	0	NA	0	NA	NA	NA
MDS-UPDRS Part II, Mean (SD)	5.0 (2.0)	6.7 (2.8)	7.9 (6.1)	8.9 (6.8)	NA	NA	-	1.0 (1.4)	NA	0.9 (1.5)	NA	NA	NA
Missing	2	1	0	0	NA	NA	1	0	NA	0	NA	NA	NA
MDS-UPDRS Part III (OFF), Mean (SD)	21.2 (5.3)	23.3 (11.8)	22.8 (14.3)	26.9 (17.9)	NA	NA	10.0 (NA)	5.3 (7.2)	NA	0.2 (0.4)	NA	NA	NA
Missing	0	7	5	2	NA	NA	0	0	NA	1	NA	NA	NA
Subthreshold Parkinsonism*, n (%)	5 (100%)	3 (100%)	4 (100%)	18 (100%)	NA	NA	1 (100%)	1 (25%)	NA	0	NA	NA	NA
Missing	0	7	5	2	NA	NA	0	0	NA	1	NA	NA	NA
MOCA Total Score, Mean (SD)	27.2 (2.5)	26.3 (2.7)	24.8 (4.7)	25.1 (5.1)	NA	NA	30.0 (NA)	28.0 (2.8)	NA	26.4 (3.2)	NA	NA	NA
On PD Treatment, n (%)	0	9 (90%)	7 (78%)	18 (90%)	NA	NA	0	0	NA	0	NA	NA	NA
Missing	0	0	0	0	NA	NA	0	0	NA	1	NA	NA	NA
UPSIT Percentile ≤ 15, n (%)	5 (100%)	9 (90%)	9 (100%)	19 (100%)	NA	NA	1 (100%)	3 (75%)	NA	4 (67%)	NA	NA	NA
Missing	0	0	0	1	NA	NA	0	0	NA	1	NA	NA	NA
Age/Sex-Expected Lowest Putamen SBR <75%, n (%)	4 (100%)	2 (100%)	1 (100%)	7 (100%)	NA	NA	1 (100%)	-	NA	0	NA	NA	NA
Missing	1	8	8	13	NA	NA	0	4	NA	2	NA	NA	NA

	PPMI (cohort at enrollment)											PASADENA	SPARK
NSD	Sporadic PD (N = 5)	LRRK2 PD (N = 10)	GBA PD (N = 9)	SNCA PD (N = 20)	PRKN PD (N = 0)	RBD (N = 0)	Hyposmia (N = 1)	LRRK2 NMC (N = 4)	GBA NMC (N = 0)	SNCA NMC (N = 7)	HC (N = 0)	Early PD (N = 0)	Early PD (N = 0)
Hoeh and Yahr Stage, n (%)													
0: Asymptomatic	0	0	0	0	NA	NA	NA	NA	NA	NA	NA	NA	NA
1: Unilateral Involvement only	3 (60%)	1 (33%)	1 (25%)	7 (39%)	NA	NA	NA	NA	NA	NA	NA	NA	NA
2: Bilateral Involvement without impairment of balance	2 (40%)	2 (67%)	1 (25%)	7 (39%)	NA	NA	NA	NA	NA	NA	NA	NA	NA
3: Mild to Moderate Involvement	0	0	2 (50%)	4 (22%)	NA	NA	NA	NA	NA	NA	NA	NA	NA
Missing	0	7	5	2	NA	NA	NA	NA	NA	NA	NA	NA	NA

* MDS-UPDRS Part III > 4 excluding postural and action tremor.

HC= Healthy controls. MDS-UPDRS=Movement Disorder Society Unified Parkinson's Disease Rating Scale. MoCA=Montreal Cognitive Assessment. PD=Parkinson's disease. NMC=non-manifesting carriers. RBD=REM sleep behavior disorder. SBR= Striatal Binding Ratio. UPSIT= University of Pennsylvania Smell Identification Test

Supplement Table 4. NSD stage by Hoehn and Yahr stage among PPMI participants with PD phenotype

Variable	Hoehn and Yahr (OFF) stage*		
	1 (N = 236)	**2** (N = 392)	**3** (N = 7)
NSD stage, n (%)			
0	0	0	0
1A	0	0	0
1B	0	0	0
2A	0	2 (1%)	0
2B	81 (34%)	62 (16%)	0
3	137 (58%)	261 (67%)	2 (29%)
4	16 (7%)	64 (16%)	5 (71%)
5	2 (1%)	2 (1%)	0
6	0	1 (<1%)	0

* Hoehn & Yahr (OFF) stage was not collected at baseline for 26 participants

*PPMI STUDY TEAMS/CORES/COLLABORATORS FOR PUBLICATIONS

Executive Steering Committee:
Kenneth Marek, MD[1] (Principal Investigator); Caroline Tanner, MD, PhD[9]; Tanya Simuni, MD[3]; Andrew Siderowf, MD, MSCE[12]; Douglas Galasko, MD[27]; Lana Chahine, MD[41]; Christopher Coffey, PhD[4]; Kalpana Merchant, PhD[61]; Kathleen Poston, MD[40]; Roseanne Dobkin, PhD[43]; Tatiana Foroud, PhD[15]; Brit Mollenhauer, MD[8]; Dan Weintraub, MD[12]; Ethan Brown, MD[9]; Karl Kieburtz, MD, MPH[23]; Mark Frasier, PhD[6]; Todd Sherer, PhD[6]; Sohini Chowdhury, MA[6]; Roy Alcalay, MD[36] and Aleksandar Videnovic, MD[47]

Steering Committee:
Duygu Tosun-Turgut, PhD[9]; Werner Poewe, MD[7]; Susan Bressman, MD[14]; Jan Hammer[15]; Raymond James, RN[22]; Ekemini Riley, PhD[42]; John Seibyl, MD[1]; Leslie Shaw, PhD[12]; David Standaert, MD, PhD[18]; Sneha Mantri, MD, MS[62]; Nabila Dahodwala, MD[12]; Michael Schwarzschild[47]; Connie Marras[45]; Hubert Fernandez, MD[25]; Ira Shoulson, MD[23]; Helen Rowbotham[2]; Paola Casalin[11] and Claudia Trenkwalder, MD[8]

Michael J. Fox Foundation (Sponsor): Todd Sherer, PhD; Sohini Chowdhury, MA; Mark Frasier, PhD; Jamie Eberling, PhD; Katie Kopil, PhD; Alyssa O'Grady; Maggie McGuire Kuhl; Leslie Kirsch, EdD and Tawny Willson, MBS

Study Cores, Committees and Related Studies:
Project Management Core: Emily Flagg, BA[1]
Site Management Core: Tanya Simuni, MD[3]; Bridget McMahon, BS[1]
Strategy and Technical Operations: Craig Stanley, PhD[1]; Kim Fabrizio, BA[1]
Data Management Core: Dixie Ecklund, MBA, MSN[4]; Trevis Huff, BSE[4]
Screening Core: Tatiana Foroud, PhD[15]; Laura Heathers, BA[15]; Christopher Hobbick, BSCE[15]; Gena Antonopoulos, BSN[15]
Imaging Core: John Seibyl, MD[1]; Kathleen Poston, MD[40]
Statistics Core: Christopher Coffey, PhD[4]; Chelsea Caspell-Garcia, MS[4]; Michael Brumm, MS[4]
Bioinformatics Core: Arthur Toga, PhD[10]; Karen Crawford, MLIS[10]
Biorepository Core: Tatiana Foroud, PhD[15]; Jan Hamer, BS[15]
Biologics Review Committee: Brit Mollenhauer[8]; Doug Galasko[27]; Kalpana Merchant[61]
Genetics Core: Andrew Singleton, PhD[13]
Pathology Core: Tatiana Foroud, PhD[15]; Thomas Montine, MD, PhD[40]
Found: Caroline Tanner, MD PhD[9]
PPMI Online: Carlie Tanner, MD PhD[9]; Ethan Brown, MD[9]; Lana Chahine, MD[41]; Roseann Dobkin, PhD[43]; Monica Korell, MPH[9]

Site Investigators:

Charles Adler, PhD[51]; Roy Alcalay, MD[36]; Amy Amara, PhD[52]; Paolo Barone, PhD[30]; Bastiaan Bloem, PhD[60] Susan Bressman, MD[14]; Kathrin Brockmann, MD[26]; Norbert Brüggemann, MD[59]; Lana Chahine, MD[41]; Kelvin Chou, MD[44]; Nabila Dahodwala, MD[12]; Alberto Espay, MD[32]; Stewart Factor, DO[16]; Hubert Fernandez, MD[25]; Michelle Fullard, MD[52]; Douglas Galasko, MD[27]; Robert Hauser, MD[19]; Penelope Hogarth, MD[17]; Shu-Ching Hu, PhD[21]; Michele Hu, PhD[58]; Stuart Isaacson, MD[31]; Christine Klein, MD[59]; Rejko Krueger, MD[2]; Mark Lew, MD[49]; Zoltan Mari, MD[56]; Connie Marras, PhD[45]; Maria Jose Martí, PhD[34]; Nikolaus McFarland, PhD[54]; Tiago Mestre, PhD[46]; Brit Mollenhauer, MD[8]; Emile Moukheiber, MD[28]; Alastair Noyce, PhD[63] Wolfgang Oertel, PhD[64]; Njideka Okubadejo, MD[65]; Sarah O'Shea, MD[39]; Rajesh Pahwa, MD[48]; Nicola Pavese, PhD[57]; Werner Poewe, MD[7]; Ron Postuma, MD[55]; Giulietta Riboldi, MD[53]; Lauren Ruffrage, MS[18]; Javier Ruiz Martinez, PhD[35]; David Russell, PhD[1]; Marie H Saint-Hilaire, MD[22]; Neil Santos, BS[51]; Wesley Schlett[47]; Ruth Schneider, MD[23]; Holly Shill, MD[50]; David Shprecher, DO[24]; Tanya Simuni, MD[3]; David Standaert, PhD[18]; Leonidas Stefanis, PhD[38]; Yen Tai, PhD[29]; Caroline Tanner, PhD[9]; Arjun Tarakad, MD[20]; Eduardo Tolosa PhD[34] and Aleksandar Videnovic, MD[47]

Coordinators:

Susan Ainscough, BA[30]; Courtney Blair, MA[18]; Erica Botting[19]; Isabella Chung, BS[56]; Kelly Clark[24]; Ioana Croitoru[35]; Kelly DeLano, MS[32]; Iris Egner, PhD[7]; Fahrial Esha, BS[53]; May Eshel, MSc[36]; Frank Ferrari, BS[44]; Victoria Kate Foster[57]; Alicia Garrido, MD[34]; Madita Grümmer[59]; Bethzaida Herrera[50]; Ella Hilt[26]; Chloe Huntzinger, BA[52]; Raymond James, BS[22]; Farah Kausar, PhD[9]; Christos Koros, MD, PhD[38]; Yara Krasowski, MSc[60]; Dustin Le, BS[17]; Ying Liu, MD[52]; Taina M. Marques, PhD[2]; Helen Mejia Santana, MA[39]; Sherri Mosovsky, MPH[41]; Jennifer Mule, BS[25]; Philip Ng, BS[45]; Lauren O'Brien[48]; Abiola Ogunleye, PGDip[29]; Oluwadamilola Ojo, MD[65]; Obi Onyinanya, BS[28]; Lisbeth Pennente, BA[31]; Romina Perrotti[55]; Michael Pileggi, MS[55]; Ashwini Ramachandran, MSc[12]; Deborah Raymond, MS[14]; Jamil Razzaque, MS[58]; Shawna Reddie, BA[46]; Kori Ribb, BSN[28]; Kyle Rizer, BA[54]; Janelle Rodriguez, BS[27]; Stephanie Roman, HS[1]; Clarissa Sanchez, MPH[20]; Cristina Simonet, PhD[29]; Anisha Singh, BS[23]; Elisabeth Sittig, RN[64]; Barbara Sommerfeld MSN[16]; Angela Stovall, BS[44]; Bobbie Stubbeman, BS[32]; Alejandra Valenzuela, BS[49]; Catherine Wandell, BS[21]; Diana Willeke[8]; Karen Williams, BA[3] and Dilinuer Wubuli, MB[45]

Partners Scientific Advisory Board (Acknowledgement)

Funding: PPMI – a public-private partnership – is funded by the Michael J. Fox Foundation for Parkinson's Research and funding partners, including 4D Pharma, Abbvie, AcureX, Allergan, Amathus Therapeutics, Aligning Science Across Parkinson's, AskBio, Avid Radiopharmaceuticals, BIAL, Biogen, Biohaven, BioLegend, BlueRock Therapeutics, Bristol-Myers Squibb, Calico Labs, Celgene, Cerevel Therapeutics, Coave Therapeutics, DaCapo Brainscience, Denali, Edmond J. Safra Foundation, Eli Lilly, Gain Therapeutics, GE

HealthCare, Genentech, GSK, Golub Capital, Handl Therapeutics, Insitro, Janssen Neuroscience, Lundbeck, Merck, Meso Scale Discovery, Mission Therapeutics, Neurocrine Biosciences, Pfizer, Piramal, Prevail Therapeutics, Roche, Sanofi, Servier, Sun Pharma Advanced Research Company, Takeda, Teva, UCB, Vanqua Bio, Verily, Voyager Therapeutics, the Weston Family Foundation and Yumanity Therapeutics.**

Institute for Neurodegenerative Disorders, New Haven, CT
University of Luxembourg, Luxembourg
Northwestern University, Chicago, IL
University of Iowa, Iowa City, IA
VectivBio AG
The Michael J. Fox Foundation for Parkinson's Research, New York, NY
Innsbruck Medical University, Innsbruck, Austria
Paracelsus-Elena Klinik, Kassel, Germany
University of California, San Francisco, CA
Laboratory of Neuroimaging (LONI), University of Southern California
BioRep, Milan, Italy
University of Pennsylvania, Philadelphia, PA
National Institute on Aging, NIH, Bethesda, MD
Mount Sinai Beth Israel, New York, NY
Indiana University, Indianapolis, IN
Emory University of Medicine, Atlanta, GA
Oregon Health and Science University, Portland, OR
University of Alabama at Birmingham, Birmingham, AL
University of South Florida, Tampa, FL
Baylor College of Medicine, Houston, TX
University of Washington, Seattle, WA
Boston University, Boston, MA
University of Rochester, Rochester, NY
Banner Research Institute, Sun City, AZ
Cleveland Clinic, Cleveland, OH
University of Tübingen, Tübingen, Germany
University of California, San Diego, CA
Johns Hopkins University, Baltimore, MD
Imperial College of London, London, UK
University of Salerno, Salerno, Italy
Parkinson's Disease and Movement Disorders Center, Boca Raton, FL
University of Cincinnati, Cincinnati, OH
Hospital Clinic of Barcelona, Barcelona, Spain
Hospital Universitario Donostia, San Sebastian, Spain
Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
St. Olav's University Hospital, Trondheim, Norway
National and Kapodistrian University of Athens, Athens, Greece
Columbia University Irving Medical Center, New York, NY
Stanford University, Stanford, CA
University of Pittsburgh, Pittsburgh, PA
Center for Strategy Philanthropy at Milken Institute, Washington D.C.
12, New Brunswick, NJ
University of Michigan, Ann Arbor, MI
Toronto Western Hospital, Toronto, Canada
The Ottawa Hospital, Ottawa, Canada
Massachusetts General Hospital, Boston, MA
University of Kansas Medical Center, Kansas City, KS
University of Southern California, Los Angeles, CA
Barrow Neurological Institute, Phoenix, AZ
Mayo Clinic Arizona, Scottsdale, AZ
University of Colorado, Aurora, CO
NYU Langone Medical Center, New York, NY
University of Florida, Gainesville, FL
Montreal Neurological Institute and Hospital/McGill, Montreal, QC, Canada
Cleveland Clinic-Las Vegas Lou Ruvo Center for Brain Health, Las Vegas, NV
Clinical Ageing Research Unit, Newcastle, UK
John Radcliffe Hospital Oxford and Oxford University, Oxford, UK
Universität Lübeck, Luebeck, Germany
Radboud University, Nijmegen, Netherlands
TransThera Consulting

Duke University, Durham, NC
Wolfson Institute of Population Health, Queen Mary University of London, UK
Philipps-University Marburg, Germany
University of Lagos, Nigeria

REFERENCES

1.   Simuni T, Chahine LM, Poston K, et al. A biological definition of neuronal alpha-synuclein disease: towards an integrated staging system for research. *Lancet neurology* 2024; **23**(2): 178-90.
2.   Siderowf A, Concha-Marambio L, Lafontant DE, et al. Assessment of heterogeneity among participants in the Parkinson's Progression Markers Initiative cohort using alpha-synuclein seed amplification: a cross-sectional study. *Lancet neurology* 2023; **22**(5): 407-17.
3.   Postuma RB, Berg D, Stern M, et al. MDS clinical diagnostic criteria for Parkinson's disease. *Mov Disord* 2015; **30**(12): 1591-601.
4.   McKeith IG, Boeve BF, Dickson DW, et al. Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium. *Neurology* 2017; **89**(1): 88-100.
5.   Marek K, Chowdhury S, Siderowf A, et al. The Parkinson's progression markers initiative (PPMI) - establishing a PD biomarker cohort. *Ann Clin Transl Neurol* 2018; **5**(12): 1460-77.
6.   Pagano G, Taylor KI, Anzures-Cabrera J, et al. Trial of Prasinezumab in Early-Stage Parkinson's Disease. *N Engl J Med* 2022; **387**(5): 421-32.
7.   Lang AE, Siderowf AD, Macklin EA, et al. Trial of Cinpanemab in Early Parkinson's Disease. *N Engl J Med* 2022; **387**(5): 408-20.
8.   Brumm MC, Pierz KA, Lafontant DE, et al. Updated Percentiles for the University of Pennsylvania Smell Identification Test in Adults 50 Years of Age and Older. *Neurology* 2023; **100**(16): e1691-e701.
9.   Nasreddine ZS, Phillips NA, Bedirian V, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. *J Am Geriatr Soc* 2005; **53**(4): 695-9.
10.   Goetz CG, Tilley BC, Shaftman SR, et al. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. *Mov Disord* 2008; **23**(15): 2129-70.
11.   Concha-Marambio L, Pritzkow S, Shahnawaz M, Farris CM, Soto C. Seed amplification assay for the detection of pathologic alpha-synuclein aggregates in cerebrospinal fluid. *Nat Protoc* 2023; **18**(4): 1179-96.
12.   Concha-Marambio L, Wang F, Armijo E, et al. Development of a methodology for large-scale production of prions for biological and structural studies. *Front Mol Biosci* 2023; **10**: 1184029.
13.   Concha-Marambio L, Weber S, Farris CM, et al. Accurate Detection of alpha-Synuclein Seeds in Cerebrospinal Fluid from Isolated Rapid Eye Movement Sleep Behavior Disorder and Patients with Parkinson's Disease in the DeNovo Parkinson (DeNoPa) Cohort. *Mov Disord* 2023; **38**(4): 567-78.
14.   Concha-Marambio L, Farris CM, Holguin B, et al. Seed Amplification Assay to Diagnose Early Parkinson's and Predict Dopaminergic Deficit Progression. *Mov Disord* 2021; **36**(10): 2444-6.
15.   Seibyl JP, Marek K, Sheff K, et al. Iodine-123-beta-CIT and iodine-123-FPCIT SPECT measurement of dopamine transporters in healthy subjects and Parkinson's patients. *J Nucl Med* 1998; **39**(9): 1500-8.
16.   Brumm MC, Siderowf A, Simuni T, et al. Parkinson's Progression Markers Initiative: A Milestone-Based Strategy to Monitor Parkinson's Disease Progression. *J Parkinsons Dis* 2023; **13**(6): 899-916.

Contributors and Author Roles

TD, GP, KP, DW, LC, CT, CK, YX, SC, LC-M, PD, TF, MF, DJ, KK, KM, BM, TM, KN, JS, TSh, ASin, DS, MS, CS, ET, ASi, BD, TSi, KM contributed to the conceptualization. MB, CG, LC, CC, ASid, BD, TSi and KMa contributed to the data curation, formal analysis and validation. TD, GP, CG, KP, DW, LC, CT, LC-M, PD, TF, DJ, KK, KM, BM, TM, KN, JS, ASin, DS, MS, CS, ET, ASi, BD, TSi, KMa contributed to the supervision. MB, CG, LC, CC, ASid, BD, TSi and KMa contributed to the writing of the original draft. CK, YX, SC, MF and TSh acquired funding, provided resources and contributed to the project administration. All authors contributed to the investigations, methodology and the review and editing of the final version of the manuscript. TD and TSi have had direct access to and verified all components of the submitted manuscript.

Declaration of Interests

TD declares former employment for and employee stock options in Biogen. GP declares employment for F. Hoffmann-La Roche Ltd. and stock ownership for F. Hoffmann-La Roche Ltd., Atea, Novartis and Eli Lilly. MB declares travel grants from The Michael J. Fox Foundation. CG declares employment for The Michael J. Fox Foundation. KP declares consultancies for Curasen; was on a scientific advisory board for Curasen and Amprion; honoraria from invited scientific presentations to universities and professional societies not exceeding $5000 per year from California Congress of Clinical Neurology, California Neurological Society, and Johns Hopkins University; and patents or patent applications numbers 17/314,979 and 63/377,293. KP also declares grants to her institution (Stanford University School of Medicine) from NIH/NINDS NS115114, NS062684, NS075097, NIH/NIA U19 AG065156, P30 AG066515, The Michael J. Fox Foundation, Lewy Body Dementia Association, Alzheimer's Drug Discovery Foundation, Sue Berghoff LBD Research Fellowship and the Knight Initiative for Brain Resilience. DW declares salary support from The Michael J. Fox Foundation for serving on an Executive Steering Committee for the PPMI and consultancies for Roche Pharma. LC declares grants to her institution from Biogen (clinical trial funding), MJFF, UPMC Competitive Medical Research Fund, National Institutes of Health, and University of Pittsburgh; grant and travel support from MJFF; royalties from Wolters Kluwel (for authorship); and in-kind donation by Advanced Brain Monitoring of equipment for research study to her institution. CC declares grants from The Michael J. Fox Foundation and NIH/NINDS. CT declares consultancies for CNS Ratings, Australian Parkinson's Mission, Biogen, Evidera, Cadent (data safety monitoring board), Adamas (steering committee), Biogen (via the Parkinson Study Group steering committee), Kyowa Kirin (advisory board), Lundbeck (advisory board), Jazz/Cavion (steering committee), Acorda (advisory board), Bial (DMC) and Genentech. CT also declares grant support to her institution from The Michael J. Fox Foundation, National Institute of Health, Gateway LLC, Department of Defense, Roche Genentech, Biogen, Parkinson Foundation and Marcus Program in Precision Medicine. CK declares employment for The Michael J. Fox Foundation. YX declares employment for and travel grants from The Michael J. Fox Foundation. SC declares employment for and travel grants from The Michael J. Fox Foundation. LC-M declares employment for and employee stock options in Amprion, grants 16712 and 21233 from The Michael J. Fox Foundation to his institution; grant U44NS111672 from NIH to his institution; and patents or patent application numbers US 20210277076A1, US 20210311077A1, US 20190353669A1 and US 20210223268A1. PD has no declarations. TF declares travel grants and grant payments to her institution (Indiana University) from The Michael J. Fox Foundation. MF declares employment for The Michael J. Fox Foundation and an unpaid advisory role at Vaxxinity. DJ declares employment for and employee stock options from Denali Therapeutics. KK declares support to his institution (University of Rochester Medical Center) from The Michael J. Fox Foundation. KMe declares consultancies for The Michael J. Fox Foundation, AcuRx, Caraway, Cerebral Therapeutics, NRG Therapeutics (scientific advisory board), Nitrase Therapeutics (scientific advisory board), Nurabio, Retromer Therapeutics (director on the board, part-time chief scientific officer), Schrodinger, Sinopia Biosciences (scientific advisory board), and Vanqua Biosciences (scientific advisory board); stock ownership for Cognition Therapeutics, Eli Lilly (retiree stock holder), Envisagenics, Nitrase Therapeutics, Sinopia Biosciences and Retromer Therapeutics; honoraria for the University of Utah; patents or patent applications for Retromer Therapeutics (planned patent); research grant from The Michael J. Fox Foundation and travel grants from the University of Utah. BM declares consultancies from Roche and Biogen; grants from The Michael J. Fox Foundation, ASAP and DFG; honoraria for Abbvie and Bial; leadership role for The Michael J. Fox Foundation and travel grants for Abbvie. TM declares support to his institution (Stanford University School of Medicine) from The Michael J. Fox Foundation.   KN declares grant to her institution from The Michael J. Fox Foundation. JS declares consultancies from Invicro, Biogen, and Abbvie; and stock ownership

from RealmIDX, MNI Holdings, and LikeMinds as well as grants from The Michael J. Fox Foundation. TSh declares employment for The Michael J. Fox Foundation. ASin declares employment for The National Institutes of Health who received grants from The Michael J. Fox Foundation and ASAP. ASin declares Diagnostic for Stroke royalties (unrelated to current work); honoraria from Movement Disorders Society and Nature Publishing Group; travel grants from Chan Zuckerberg Initiative, The Michael J. Fox Foundation and Weill Cornell. ASin's spouse is an employee of GeneDx. DS has no declarations. MS declared consultancies for Mediflix, Inc., Health and Wellness Partners; honoraria from Atria Foundation, International Parkinson and Movement Disorder Society, Neurocrine, Luye Pharma and Acorda. MS serves on advisory board at Neuroderm, Alexza, Alexion and Biogen. CS declares employment for Amprion; stock ownership for Amprion; honoraria (will receive royalties for the sale of seed amplification assay [SAA]) from Amprion; and patents or patent applications, awarded and amplified in conjunction with Amprion for the SAA assay. ET has no declarations. ASid declares consultancies for SPARC Therapeutics, Capsida Therapeutics and Parkinson Study Group; honoraria from Bial; grants from The Michael J. Fox Foundation (member of PPMI Steering Committee); and participation on board at Wave Life Sciences, Inhibikase, Prevail, Huntington Study Group and Massachusetts General Hospital. BD declarations are TBD. TSi declares consultancies for AcureX, Adamas, AskBio, Amneal, Blue Rock Therapeutics, Critical Path for Parkinson's Consortium, Denali, The Michael J. Fox Foundation, Neuroderm, Roche, Sanofi, Sinopia, Takeda, and Vanqua Bio; on advisory boards for AcureX, Adamas, AskBio, Biohaven, Denali, GAIN, Neuron23 and Roche; on scientific advisory boards for Koneksa, Neuroderm, Sanofi and UCB; and received research funding from Amneal, Biogen, Roche, Neuroderm, Sanofi, Prevail and UCB and an investigator for NINDS, MJFF, Parkinson's Foundation. KMa declares support to his institution (Institute for Neurodegenerative Disorders) from The Michael J. Fox Foundation. KMa also declares consultancies for Invicro, The Michael J. Fox Foundation, Roche, Calico, Coave, Neuron23, Orbimed, Biohaven, Anofi, Koneksa, Merck, Lilly, Inhibikase, Neuramedy, IRLabs and Prothena and participates on DSMB at Biohaven.